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Imaging (MPI)Abstract Introduction: Intradialytic hypotension (IDH) remains to be a major complication of
hemodialysis occurring in nearly 25% of dialysis sessions. It is a signiﬁcant independent factor
affecting mortality in hemodialysis patients. Autonomic nervous system dysfunction, blood seques-
tration in the setting of hypovolemia, cardiovascular diseases and increased plasma level of end
products of nitric oxide metabolism are possible causes. In this controlled prospective study we
examined patients with chronic renal failure and intradialytic hypotension to evaluate the relation-
ship between this hypotension and myocardial ischemia after controlling other possible causes.
Materials and methods: Thirty patients with chronic renal failure who are on regular dialysis
were enrolled. Before dialysis, patients were subjected to history taking and clinical examination.
Echocardiography and several lab tests were done. Glomerular ﬁltration rate (GFR) was calculated
using Cockcroft’s and Gault formula. Autonomic dysfunction was also assessed. The dialysis ses-
sion was standardized in all patients. Intradialytic blood pressure was monitored and hypotension
was classiﬁed as mild (SBP > 100 mmHg), moderate (SBP 80–100) or severe (SBP < 80). After
dialysis, myocardial ischemia was assessed using stress myocardial perfusion imaging (MPI) (Phar-
macologic stress testing using Dipyridamole) and is further classiﬁed as mild, moderate or severe
ischemia. Patients with sepsis, hemoglobin level less than 9 g/dL, diabetes mellitus, low cardiac out-
put, coronary artery disease, signiﬁcant valvular lesion or body weight below the dry weight of the
patient were excluded from the study. Bronchial asthma, emphysema and severe COPD are contra-
indications to Dipyridamole and thus were also excluded from the study.
14 R.A. Soliman et al.Results: Twenty patients had no or mild intradialytic hypotension whereas ten patients had
moderate or severe hypotension. Among the ﬁrst group, only two patients (10%) were found to
have myocardial ischemia, while in the latter group, seven patients (70%) had myocardial ischemia that’s
mostly moderate (p= 0.002). Stress induced LV dysfunction was also signiﬁcantly prevalent in patients
with moderate or severe intradialytic hypotension as opposed to other group (p= 0.002) LVED.
Conclusions: Patients with CKD and regular hemodialysis who experience moderate or severe
intradialytic hypotension have signiﬁcantly higher prevalence of myocardial ischemia and stress
induced myocardial dysfunction, than those who experience no or mild intradialytic hypotension.
Open access under CC BY-NC-ND license.
4© 201  The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V.Table 1 Baseline characteristics of the study group (n= 30).
Parameter Value [N (%) or mean ± SD]
Age (years) 44 ± 13





History of chest pain 6 (20)
Family history of IHD 9 (30)
Autonomic neuropathy 9 (30)
AV ﬁstula 23 (77)
Duration of hemodialysis (years) 3.7 ± 2.1
ECG and ECHO
Arrhythmia in ECG 4 (13)
LVH in ECG 6 (20)
RWMA 5 (17)
LVEDD (mm) 49.7 ± 5.4
LVESD (mm) 32.4 ± 4





Urine speciﬁc gravity* 1009 ± 2.1
Labs
Hb (g/dL) 10.5 ± 0.73
Hct (%) 32.6 ± 2.9
TLC (103 cells/cmm) 6.1 ± 2.1
FBS (mg/dL) 70.2 ± 11.2
PPBS (mg/dL) 123.5 ± 15.2
HB A1C (mg/dL) 5 ± 0.59
Serum Triglycerides (mg/dL) 109.7 ± 43
Serum Cholesterol (mg/dL) 151 ± 60
Serum Urea (mg/dL) 129.8 ± 29.7
Serum Creatinine (mg/dL) 7.9 ± 2.1
GFR (ml/min/1.73 m2) 11 ± 4.2
Serum Sodium (mEq/L) 138 ± 5.8
Serum Potassium (mEq/L) 5.2 ± 0.63
IHD, ischemic heart disease; LVH, left ventricular hypertrophy;
RWMA, regional wall motion abnormalities; LVEDD, left ventri-
cle end-diastolic diameter; LVESD, left ventricle end-systolic
diameter; EF, ejection fraction Hb, hemoglobin; Hct, hematocrit;
TLC, total leukocytic count; FBS, fasting blood sugar; PPBS, post
prandial blood sugar; HB A1C, hemoglobin A1C; GFR, glomerular
ﬁltration rate.
* Done only for the 15 patients who were not anuric.1. Introduction
Intradialytic hypotension (IDH) remains to be a major compli-
cation of hemodialysis. It occurs in nearly 25% of dialysis ses-
sions [1] and often requires aggressive resuscitative measures
and sometimes premature termination of hemodialysis. It is
also a signiﬁcant independent factor affecting mortality in
hemodialysis patients [2].
Despite the advances of machines with ultraﬁltration con-
trol devices, modifying dialysate composition, temperature
control, correction of nutritional deﬁciencies and treatment
of anemia with erythropoietin therapy, many patients still have
episodes of intradialytic hypotension. Among other factors,
the major pathophysiology of these episodes is the removal
of large volume of blood water and solutes over a short period
of time, overwhelming normal compensatory mechanisms,
which include plasma reﬁlling and reduction of venous capac-
ity (due to reduction of pressure transmission to veins).
In some patients, a seemingly paradoxical and inappropri-
ate reduction of sympathetic tone may occur, causing
reduction of arteriolar resistance, decreased transmission of
pressure to veins with corresponding increase in venous capac-
ity. Increased sequestration of blood in veins under conditions
of hypovolemia reduces cardiac ﬁlling, cardiac output and ulti-
mately blood pressure. Hypotensive episodes during hemodial-
ysis in patients with end stage renal disease in absence of
inadequate maintenance of the plasma volume, pre-existence
of cardiovascular disease, or autonomic nervous system dys-
function are accompanied by increased plasma concentrations
of the end-products of nitric oxide metabolism (above the
expected levels, based on the reduction of urea [3]).
In this controlled prospective study, patients with chronic
renal failure and intradialytic hypotension episodes were
thoroughly investigated, to evaluate the relationship between
hypotension and myocardial ischemia after controlling other
possible causes.
2. Patients and methods
This prospective study was conducted in King Fahd Hemodi-
alysis unit in Kasr Al-Aini hospital, Hemodialysis Unit in Al-
Zahraa hospital and Critical Care Medicine Department in
Kasr Al-Aini hospital over the time period from February
2010 to June 2011. All patients included in the study provided
informed written consent. The study includes 30 patients with
chronic renal failure who receive regular hemodialysis sessions.
Twenty patients developed hypotension during hemodialysis
session, and the remaining 10 patients did not develop
Figure 1 Myocardial ischemia diagnosed by MPI in patients with moderate or severe intradialytic hypotension, in comparison to those
with no or mild hypotension (p= 0.002).
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assessed in all patients using stress myocardial perfusion imag-
ing (MPI) (Pharmacologic stress testing using Dipyridamole).
Patients with sepsis, hemoglobin level less than 9 g/dL,
diabetes mellitus, low cardiac output, acute coronary syn-
drome, signiﬁcant valvular lesion or body weight below the
dry weight of the patient were excluded from the study.
Bronchial Asthma, emphysema and severe COPD are contra-
indications to Dipyridamole and thus were also excluded
from the study.
2.1. Before dialysis
All eligible patients were subjected to full history taking and
clinical examination. Serum Urea and Creatinine were mea-
sured. Glomerular ﬁltration rate (GFR) was calculated using
Cockcroft’s and Gault equation. Autonomic dysfunction was
assessed using at least 2 of the following tests; blood pressure
(BP) response to standing, BP response to sustained handgrip,
Heart Rate (HR) response to standing, HR response to deep
breathing and HR response to valsalva. Positive result of
any test indicates autonomic dysfunction [4].
2.2. During dialysis
Dialysis was done via AV ﬁstula (23 patients) or dialysis cath-
eter (7 patients), using Fresenius 4008B, Nipro machine with
ultraﬁltration volume control and polysulfone, Fresenius F6
ﬁlters. Temperature of dialysate was kept at 36 C. Blood
pump was kept between 250 and 350 ml/min except during
the hypotensive episodes during which the blood pump was
decreased to only 200 ml/min and not less to insure adequate
dialysis session. Dialysate ﬂow was 500 ml/min. All dialysis
sessions lasted around 4 h.
BP is recorded using standard sphygmomanometer every
30 min in supine position. Each time the mean of 3 measure-
ments is recorded. Intradialytic hypotension is deﬁned as
symptomatic decrease of more than 30 mmHg in systolic blood
pressure or as an absolute systolic blood pressure under
90 mmHg [5]. Hypotension is further classiﬁed as mild
(Systolic Blood Pressure (SBP) > 100 mmHg), moderate
(SBP 80–100 mmHg) and Severe (SBP < 80 mmHg) [6].Patients who required vasopressors were unstable and
accordingly were excluded from this study.
2.3. After dialysis
Within 2–5 h after dialysis, patients hadboth trans-thoracic echo-
cardiography and MPI. The echo was done using ATL machine
HDI 5000 with the patient lying in the left lateral decubitus using
a 3.5 MHZ probe. MPI was done at nuclear laboratory of the
critical care medicine department, Kasr Al-Aini hospital, Cairo
University utilizing the ‘‘freeze imaging protocol’’. The set of
SPECT images was acquired using a triple head Siemens gamma
camerawith high resolution collimators (model Symbia E). Phar-
macological stress testing using Dipyridamole was done as most
patients with CKD could not achieve target HR during treadmill
stress testing due to marked physical limitations.
Patients were instructed to fast for at least 6–8 h, stop the-
ophylline medications for at least 24 h and not to have any caf-
feinated drinks or beverages for at least 24 h prior to the study.
Dipyridamole 0.56 mg/kg was diluted with 40 cc normal saline
and infused over 4 min. 2 min later, 20–25 mCi Tc-99 mSestam-
ibi were injected intravenously through a wide bore cannula fol-
lowed by saline ﬂush. Patients were monitored for at least 5 min
or till vital signs returned to baseline. Ambulant patients were
asked to walk for 4 min after Dipyridamole infusion.
Twenty projections were acquired (30 s for each frame) at
120 degree arc and total acquisition time of 12 min. SPECT
images were processed using the back-projection technique to
get trans-axial images then short axis, vertical long axis and
horizontal long axis cuts. The twenty-segment scoring system
was applied to estimate the Myocardium At Risk (MAR),
and the severity of perfusion defect was assessed for each
segment using a ‘‘0–4’’ scoring system with ‘‘0’’ indicating
normal perfusion and ‘‘4’’ indicating no photon activity. The
sum of these scores is the Summed Stress Score (SSS).
Seventy two hours later, patients were re-injected with 20–
30 mCi Tc-99 m Sestamibi intravenously to acquire the second
set of SPECT images at rest, and to estimate the left ventricular
ejection fraction (EF) utilizing Gated SPECT technique. The
severity of perfusion defects of MAR in this set of SPECT images
is assessed similarly and the sumof these scores is the SummedRest
Score (SRS).
Table 2 Comparison of demographic, clinical, laboratory and MPI data between the 2 study groups.
Parameter Group A (n= 20) Group B (n= 10)
Age (years) 43.5 (33–54) 47.5 (28–58) 0.63
Weight (Kg) 65.5 (56–73) 67 (58–77) 0.81
Male 9 (45) 3 (30) 0.69
Clinical
Smokers 5 (25) 2 (20) 1.0
Hypertension 7 (35) 5 (50) 0.69
Family history of IHD 5 (25) 4 (20) 0.43
Autonomic neuropathy 4 (20) 5 (50) 0.115
AV ﬁstula 16 (80) 7 (70) 0.66
Duration of hemodialysis (years) 4 (3–6) 2.5 (1–4) 0.1
ECG and ECHO
Arrhythmia in ECG 1 (5) 3 (30) 0.095
LVH in ECG 3 (15) 3 (30) 0.37
RWMA 2 (10) 3 (30) 0.30
LVEDD (mm) 52 (46.5–55) 44.5 (44–51) 0.046
LVESD (mm) 32 (30–35) 31.5 (28–34) 0.63
EF (%) 63 (56–70) 59.5 (56–62) 0.19
Grades of Albuminuria* n = 8 n = 7
(+) 5/8 (62.5) 1/7 (14.3) 0.092
(++) 3/8 (37.5) 4/7 (57.1)
(+++) 0/8 2/7 (28.6)
Urine speciﬁc gravity 1010 (1008–1010) 1009 (1005–1010) 0.12
Labs
Hb (g/dL) 10.4 (9.8–10.9) 10.5 (10.3–11.3) 0.15
Hct (%) 31.9 (30.3–35) 33 (32.3–37) 0.098
TLC (103 cells/cmm) 5.4 (4.8–7.6) 5.2 (4–8) 0.74
FBS (mg/dL) 71 (60–80) 69 (62–76) 0.88
PPBS (mg/dL) 123 (116–131) 119 (108–134) 0.58
HB A1C (mg/dL) 4.9 (4.6–5.5) 4.8 (4.3–5.5) 0.42
Serum Triglycerides (mg/dL) 90.5 (80–117) 97 (75–170) 0.75
Serum Cholesterol (mg/dL) 135 (113–165) 117 (109–247) 0.55
Serum Urea (mg/dL) 138 (101–151) 121 (106–144) 0.4
Serum Creatinine (mg/dL) 8.4 (6.3–9.7) 7.7 (6.5–9) 0.63
GFR (ml/min/1.73 m2) 10.2 (7.9–12.4) 9.5 (8.9–12.6) 0.55
Serum Sodium (mEq/L) 138.5 (133–144) 138.5 (133–142) 1.0
Serum Potassium (mEq/L) 5.2 (4.7–5.5) 5.3 (5–6.1) 0.094
MPI
Ischemia (total count) 2 (10) 7 (70) 0.002
Mild ischemia 1/1 (50) 1/7 (14.3) 0.417
Moderate ischemia 1/1 (50) 6/7 (85.7)
Scar 0 2 (20) 0.103
Stress induced LV dysfunction 2 (10) 7 (70) 0.002
Data are displayed as n (%) or median (inter-quartile range).
IHD, ischemic heart disease; LVH, left ventricular hypertrophy; RWMA, regional wall motion abnormalities; LVEDD, left ventricle end-
diastolic diameter; LVESD, left ventricle end-systolic diameter; EF, ejection fraction; Hb, hemoglobin; Hct, hematocrit; TLC, total leukocytic
count; FBS, fasting blood sugar; PPBS, post prandial blood sugar; HB A1C, hemoglobin A1C; GFR, glomerular ﬁltration rate.
* Done only for the 15 patients who were not anuric.
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ence Score (SDS). It is classiﬁed as follows; 0–4 indicates no
ischemia, 5–8 mild ischemia, 9–12 moderate ischemia and
more than 12 is severe ischemia.2.4. Statistical methods
Statistical analysis was done using Statistical Package for
Social Sciences (SPSS) software, release 16.0.0 for Windows
(SPSS Inc., Chicago, Illinois).Categorical variables are described as frequency (n) and
percentage (%). Quantitative variables are described as
mean ± standard deviation (SD) whenever parametric. Non-
parametric quantitative variables are described as median
and interquartile range (IQR). Bivariate analysis of categorical
variables was done using Chi-square test with Yates Continu-
ity correction for 2 · 2 tables. Whenever cell frequency is <5,
Fisher’s Exact test is used.
Comparing two groups of quantitative variables was done
using Independent-Samples Student’s t test for parametric
data, and Mann–Whitney test for non-parametric data.
Figure 2 Stress induced LV dysfunction diagnosed by MPI in patients with moderate or severe intradialytic hypotension in comparison
to those with no or mild hypotension (p= 0.002).
Figure 3 Left ventricular end-diastolic diameter in patients with moderate or severe intradialytic hypotension (44.5 mm [44–51]) in
comparison to those with no or mild intradialytic hypotension (52 mm [46.5–55]) (p= 0.046).
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value. p value <0.05 is considered statistically signiﬁcant.
3. Results
Thirty patients were included in this study. Their baseline
characteristics are listed in Table 1.
We found that 70% (7/10) of patients who had moderate or
severe hypotension (Group B) had myocardial ischemia on
MPI, in comparison to 10% (2/20) of patients who experienced
no or mild intradialytic hypotension (Group A); a difference
that is statistically signiﬁcant (p= 0.002) (Fig. 1).
Several other variables were compared across both study
groups (Table 2). It is to be noted that patients of Group B
were more likely to have stress induced LV dysfunction on
MPI (7/10, 70%) than patients of Group A (2/20, 10%)
(p= 0.002) (Fig. 2). LVED was wider in Group A (Median52 mm, IQR 46.5–55) than in Group B (44.5 mm, 44–50.75)
(p= 0.046) (Fig. 3).
4. Discussion
Intradialytic hypotension (IDH) is a major complication of
hemodialysis. Two to four liters of ﬂuid needs to be removed
during a regular session, equivalent to 40–80% of the blood
volume. It is therefore not surprising that hypotension occurs
so often. Although many factors – patient or treatment related
– play a role, a reduction of blood volume is crucial in its path-
ogenesis [1].
Hypotension is one of the clinical presentation of CVD in
patients with CKD [7]. There are a number of possible expla-
nations for the independent association of reduced GFR and
CVD outcomes. First, a reduced GFR may be associated with
an increased level of nontraditional CVD risk factors that
18 R.A. Soliman et al.frequently are not assessed in many studies. Second, reduced
GFR may be a marker of undiagnosed vascular disease or
alternatively a marker of the severity of diagnosed vascular
disease, especially in high or highest risk populations. Third,
reduced GFR may have had more severe hypertension or
dyslipidemia and therefore have suffered more vascular
damage secondary to hypertension or dyslipidemia. Fourth,
recent studies have suggested that subjects with reduced
GFR are less likely to receive medications or therapies such
as angiotensin converting enzyme inhibitors, ß-blockers,
aspirin, platelet inhibitors, thrombolytics, or percutaneous
intervention than patients with preserved GFR. Perhaps as
important was the fact that in the same studies, patients with
reduced GFR who did receive the above interventions
obtained similar beneﬁt as patients with preserved GFR.
Finally, decreased GFR itself may be a risk factor for progres-
sion of ventricular remodeling and cardiac dysfunction [7].
Different studies stated that, during hemodialysis, patients
are particularly susceptible to myocardial ischemia for number
of reasons including: LV hypertrophy [8], intradialytic hypo-
tension and instability [9], high prevalence of decrease coro-
nary ﬂow reserve even in the absence of coronary vessel
stenosis [10,11].
Hakeem et al. [12] reported that in patients with CKD 40%
of perfusion scans were abnormal (SSSP 4) with 20% mild
defects and 20% moderated to severe defects.
In line with Hakeem’s result, we found that patients who
experience moderate or severe intradialytic hypotension have
signiﬁcantly higher prevalence of myocardial ischemia (70%,
7/10), in comparison to those who have no or mild intradialyt-
ic hypotension (10%, 2/20) (p= 0.002).
Paoletti et al. [13] stated that there is growing evidence that
patients with CKD have unrecognized LV dysfunction, both
systolic and diastolic. They also pointed at the importance of
LV dysfunction (LV ejection fraction <40%) as a predictor
of cardiac death in patients with CKD.
We similarly found that CKD patients who develop moder-
ate or severe intradialytic hypotension, have signiﬁcantly
higher prevalence of stress induced LV dysfunction (70%, 7/
10) than those who have no or mild hypotensive episodes
(10%, 2/20) (p= 0.002).
Deterioration of renal function in CKD may lead to dysli-
pidemia or accumulation of uremic toxins, which can stimulate
oxidative stress and inﬂammation, which in turn contributes to
endothelial dysfunction and progression of atherosclerosis
[14]. Renal failure causes changes in plasma components and
endothelial structure and function that favor vascular injury,
which may play a role as a trigger for inﬂammatory response.
Dyslipidemia associated with CKD contributes to the inﬂam-
matory response in renal failure [15]. However, in our study
we found that levels of serum cholesterol and triglycerides were
not signiﬁcantly different between the two study groups, a
ﬁnding probably attributed to the small number of study
group and the relatively low economic standard of those
patients.
Patients with CKD also have a high prevalence of arterio-
sclerosis and remodeling of large arteries. Remodeling may
be due to either pressure overload – which is distinguished
by wall hypertrophy and an increased wall-to-lumen ratio –
or ﬂow overload, which is characterized by a proportional
increase in arterial diameter and wall thickness [16].In conclusion, we found that patients with CKD and regu-
lar hemodialysis who experience moderate or severe intradia-
lytic hypotension have signiﬁcantly higher prevalence of
myocardial ischemia and stress induced myocardial dysfunc-
tion, than those who experience no or mild intradialytic
hypotension.References
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